| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5104858 | Value in Health | 2017 | 9 Pages |
Abstract
From an Italian health care service perspective, TARE could be a cost-effective strategy in comparison with sorafenib for patients with intermediate or advanced HCC. The results from forthcoming randomized controlled trials comparing TARE with sorafenib will be able to confirm or reject the validity of this preliminary evaluation. In the meantime, decision makers can use these results to control and coordinate the diffusion of the technology.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Carla PhD, Oriana PhD, Silvia MSc, Rosanna PhD,